NRX Pharmaceuticals (NRXP) Enterprise Value (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Enterprise Value data on file, last reported at -$6.7 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 21.82% year-over-year to -$6.7 million in Q1 2026; TTM through Mar 2026 was -$6.7 million, a 21.82% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 440.33% from the prior year.
• Enterprise Value for Q1 2026 stood at -$6.7 million, up from -$7.8 million in the prior quarter.
• Over the last five years, Enterprise Value for NRXP reached as high as -$1.3 million in Q1 2024 and fell as low as -$40.2 million in Q1 2022.
• Historically, Enterprise Value has averaged -$10.8 million across 5 years, with a median of -$7.2 million in 2025.
• Across the five-year window, Enterprise Value surged 92.01% in 2024 and slumped 440.33% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$20.1 million in 2022, then surged by 77.09% to -$4.6 million in 2023, then soared by 68.6% to -$1.4 million in 2024, then slumped by 440.33% to -$7.8 million in 2025, then increased by 14.07% to -$6.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$6.7 million in Q1 2026, -$7.8 million in Q4 2025, and -$7.2 million in Q3 2025.